



Corporate Release No 434

22 April 2011

### **Lundbeck's partner Mochida receives approval of Lexapro® in Japan**

- *Lexapro® - the most prescribed branded antidepressant in the world - will now also be available to Japanese patients*
- *Clinical phase III studies in Japan have confirmed the efficacy and tolerability of Lexapro®*
- *Lundbeck expects Lexapro® in Japan to provide a meaningful contribution to Lundbeck's financial performance as early as 2012.*

H. Lundbeck A/S (Lundbeck) today announced that our partner Mochida Pharmaceutical Co., Ltd. (Mochida) has obtained approval of Lexapro® 10 mg (escitalopram) from the Japanese Ministry of Health, Labour and Welfare (MHLW).

Lundbeck has partnered with Mochida, which conducted the development of Lexapro® in Japan. Lexapro® will, as a new treatment option, contribute to improving the quality of life (QoL) of patients suffering from depression.

Mochida and Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) will co-promote the product, and Yoshitomiya Corporation, a subsidiary of Mitsubishi Tanabe, will participate in the promotion. This means that the launch will be supported by more than 2,000 sales representatives, which is fully competitive in the Japanese market. The schedule for the launch of Lexapro® will be announced after its National Health Insurance price listing.

*"We are very pleased that the Japanese authorities have approved Lexapro®, as this will soon make Lexapro® available to the many people suffering from depression in Japan," says Lundbeck Senior Vice President Ole Chrintz, International Markets. He continues: "As in the rest of the world, we are convinced that Lexapro® will prove to be a valuable treatment option for people with major depression in Japan."*

#### **The Japanese antidepressant market**

In 2010, the Japanese antidepressant market had a value of JPY 135 billion (EUR ~1bn), up 10.7% from 2009 according to IMS Japan. The three most sold antidepressants in Japan were by the end of 2010 paroxetine with a value market share of 37%, sertraline with a share of 20% and fluvoxamine with a share of 15%.

The number of patients with depression in Japan is increasing every year and is currently estimated to exceed one million. Escitalopram has been very well received by patients and doctors worldwide for the treatment of depression and will offer a new treatment option for patients with depression in Japan.

**Mochida and Lundbeck alliance**

In May 2002, Lundbeck entered into a license agreement with Mochida for the development and commercialisation of escitalopram in Japan. In January 2010, Mochida announced that the company had signed an agreement to co-promote escitalopram in Japan with Mitsubishi Tanabe.

The financial terms of the agreement have not been disclosed, but Lundbeck is to receive regulatory milestone payments and royalties on sales.

In Japan, Mochida began the development of escitalopram in 2002 and conducted clinical trials in patients with depression. The results of these studies confirmed its efficacy and tolerability, which has led to the filing and subsequent approval of escitalopram.

**Financial guidance**

The content of this release will have no influence on the Lundbeck Group's financial guidance for 2011 which was provided on 24 February 2011 in connection with the release of the financial results for 2010.



## Lundbeck contacts

### Investors:

Palle Holm Olesen  
Chief Specialist, Investor Relations  
+45 36 43 24 26

Magnus Thorstholm Jensen  
Investor Relations Officer  
+45 36 43 38 16

Jacob Tolstrup  
Vice President  
+1 847 282 5713

### Media:

Mads Kronborg  
Media Relations Manager  
+45 36 43 28 51

Simon Mehl Augustesen  
International Media Specialist  
+45 36 43 49 80

## About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit [www.lundbeck.com](http://www.lundbeck.com).